Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose reabsorption by SGLT2. Patients with type 2 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreea, Munteanu Madalina, Surabhi, Swarnkar, Razvan-Ionut, Popescu, Lucia, Ciobotaru, Camelia, Nicolae, Emil, Tufanoiu, Tiberiu, Nanea Ioan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143699/
https://www.ncbi.nlm.nih.gov/pubmed/37109700
http://dx.doi.org/10.3390/medicina59040742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143699/
https://www.ncbi.nlm.nih.gov/pubmed/37109700
http://dx.doi.org/10.3390/medicina59040742

Ejemplares similares